Kenya Releases 20 Ebola Contacts as DRC Launches Bundibugyo Vaccine Trial

After a mandatory 21‑day monitoring period, twenty people linked to Kenya's first Bundibugyo Ebola case were discharged from quarantine and reunited with their families. Health officials confirmed that all released individuals remained asymptomatic, received final health assessments and counselling on post‑discharge precautions, and pose no infection risk. A further ninety‑eight contacts continue to be monitored under the same protocol. The swift completion of quarantine for these contacts follows robust tracing that identified family members, airline passengers, crew, airport staff and medical personnel exposed since the index case returned from the DRC.

In the eastern city of Bunia, the Democratic Republic of Congo launched a clinical trial designed to evaluate several vaccine candidates against the Bundibugyo strain using a ring‑vaccination strategy. Four volunteers were vaccinated on the trial's first day, marking the start of a platform that can test multiple vaccines within a single framework. The trial includes the Ervebo vaccine, which has proven effective against the Zaire Ebola virus, though its efficacy against Bundibugyo remains uncertain. Researchers hope the study will generate data to guide policy decisions and eventually provide an effective tool for current and future outbreaks.

The World Health Organization continues to back Kenya's Ebola response, offering coordination, disease surveillance, contact tracing, laboratory testing, case management, infection prevention, health screening at points of entry and risk communication. Kenya has reported nine confirmed cases and two deaths, all linked to the same transmission chain, with no evidence of community spread. Eight contacts in Kenya have developed symptoms and were transferred to the Nairobi treatment centre. Across the border, the DRC faces an outbreak approaching ten thousand cases, underscoring the regional urgency of WHO's support for both containment measures and the vaccine trial.